The asymptomatic nature of glaucoma makes it imperative to get consistent screening to catch the condition early.
Catching glaucoma early through routine screening is the best way to get effective results from treatment for glaucoma, according to Jonathan Eisengart, MD, an ophthalmologist at Cleveland Clinic.
This transcript has been lightly edited for clarity.
Transcript
What should everyone know about glaucoma?
I think the most important thing to know is just that it's really, totally asymptomatic. That means it has no symptoms. It has no symptoms until late in the disease. So there's 2 things about glaucoma that make it a perfect disease for screening. And screening means we check a whole lot of people, and if anybody has it, we can start treatment, right? So firstly, glaucoma has years and years where it has no symptoms, and if we catch it during that time, we can do something about it. So treatment for glaucoma is much better when it's caught early. We can certainly help people when glaucoma is caught very late in the disease, but we can't reverse any damage that's already been done. So for those reasons, screening is really important. You know that means, if you're in your 40s, get an eye exam, if in your 50s get an eye exam or two, and then, once you're in your 60s, really, an eye exam every 1 to 2 years, if you don't have any other history or eye diseases, is highly recommended. Obviously, the risk for glaucoma gets more and more as you get older. And just getting your eye exam, getting checked along with your general health once a year is really important.
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More